IGSM Concludes Negotiations With Biotech Company
FORT LAUDERDALE, FL–(Marketwire – Aug 27, 2012) – IGSM Group, Inc. (PINKSHEETS: IGSM) has concluded negotiations with a Biotech Company to commercialize the opportunity presented by a small protein named Crotamine. Crotamine is a Cell Penetrating Peptide (“CPP“), which can act as a neurotoxin by attaching to sodium channels, can locate and penetrate rapidly dividing cells such as bone marrow or tumor cells, and has demonstrated toxicity to tumor cells. A recent scientific publication revealed that Crotamine could deliver genes into replicating cells in laboratory bench studies (in-vitro) and animal models (in-vivo). …. MORE
IGSM GROUP ENTHUSIASTICALLY EMBARKS ON ENTERTAINING BIOTECH ACQUISITION CANDIDATES TO MEET THE COMPANY’S STRICT CRITERIA AND BUSINESS STRATEGY.
FORT LAUDERDALE, FL–(Marketwire – Aug 15, 2012) – IGSM GROUP INC. (PINKSHEETS: IGSM) announced today the IGSM Group advisors and management have been engaging in early stage discussions about a possible acquisition of a company that has presented itself as having profit potential and synergy.
As part of its overall plan of business, IGSM is a company, currently seeking solid acquisition candidates. The candidates must meet our criteria and are also willing to enter the public markets through our incubation process. This industry space presents not only an incredible financial opportunity, management plans raise future expectations of IGSM Group company goals and shareholder value significantly.
The Biotech Industry.
According to Mr. Damien Conover, Morningstar’s associate director of health care, he believes that there is a strong group of acquirers in Big Pharma that remain very motivated to do these acquisitions. They have a huge patent cliff coming up and they just don’t have products in their own pipelines to offset that. Also, they have very strong balance sheets and cash flow generation so they have the means to acquire growth. IGSM Group is selective in choosing candidates with significant pipe-line and end market products.